The disruption of health systems during the pandemic led to an increase in clinical risks and patient harm due to the accentuation of safety gaps, interruption of essential health services, and failure to provide timely diagnosis and treatment.

Seasonal influenza viruses cause recurring global epidemics by continually evolving to escape host immunity. The viral constraints and host immune responses that limit and drive the evolution of these viruses are increasingly well understood.

The rapid evolution of SARS-CoV-2 resulted in variations in the spike that enhanced transmissibility or weakened vaccine protection.

SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells.

This investigated the monocyte and inflammatory profiles of individuals who were hospitalised with COVID-19 during the acute phase and the convalescent period.

This study demonstrates durable yet compartmentalised nasal IgA and plasma antibody responses to SARSCoV-2 after infection and subsequent vaccination.

T cell responses against infections and cancer are directed by conventional dendritic cells (cDCs) in lymph nodes distant from the site of challenge.

Nirsevimab is a monoclonal antibody that binds to the RSV fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season.

This article presents an overview of European Union (EU) statistics related to influenza.

The European Public Health Alliance have signed a memorandum of understanding with WHO Europe to enhance their partnership. Both organisations will work closely to address key health challenges and drive positive change.

A study assessing scientific, engineering, legal and economic considerations of flexible EU manufacturing and innovation of medical countermeasures for serious cross-border threats to health